Floatz logo

Talzenna

Leukemia

Dana-Farber Cancer InstitutePhase 1Active
C
37/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
65/ 100

Competitive context

124 Active assets in the Leukemia cohort.

Asset / SponsorPhaseRating
VINCRISTINE SULFATE
Inhye Ahn
Phase 3BB
MERCAPTOPURINE ANHYDROUS
Dana-Farber Cancer Institute
Phase 3BB
Daunorubicin
Richard Stone, MD
Phase 3BB
PEGASPARGASE
Dana-Farber Cancer Institute
Phase 3BB
THIOGUANINE ANHYDROUS
Incyte Corporation
Phase 3BB

View all 50 →

Same molecule, other indications

Talzenna is also rated in:

BRCA2-related cancer predispositionDormant
BB
Indicative ·
68 / 100
View asset →
castration-resistant prostate carcinomaDormant
BB
Indicative ·
65 / 100
View asset →
Her2-receptor negative breast cancerDormant
BB
Indicative ·
64 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →